Biomind Labs (BMND: NEO) Is Developing The Next Generation of Medicines For The 21st Century – The Pharmaceutical Side of Psychedelics

Alejandro Antalich, CEO of Biomind. “We, both, are driven by innovation. At Biomind, our objective is to change the course of medicine by assisting doctors in potentially saving more lives and providing a better quality of life to millions of people suffering from addiction, chronic pain, depression, anxiety, and other mental health disorders. Biomind Labs is Developing the next generation of medicines for the 21st century … the pharmaceutical side of psychedelics THE PROBLEM ● Depression and anxiety cost the global economy US$ 1 trillion each year ~ 20% of the world’s children and adolescents have a mental health condition Suicide is the second leading cause of death among 15-29 year-olds 13% rise in mental health conditions & substance use disorders in last decade (to 2017) Mental health conditions now cause 1 in 5 years lived with disability #Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety and depression amongst other things More than 80% of the global population prefers natural products as sources of new drug candidates … and that is good because Biomind’s vertical integration approach – Transforming natural psychotropic compounds into pharmaceuticals  – creating drug therapies that harness the medicinal power of natural psychedelic compounds 1 indication is already in Phase 2 … 3 indications in Phase 2 by end 2021 … 3 in Phase 3 by end 2022. Sit back, relax and listen this powerful interview with Alejandro Antalich, Chief Executive Officer of Biomind Labs.